Tilrekimig Clears EASI-75 Endpoint in Atopic Dermatitis
Tilrekimig has hit the EASI-75 primary endpoint in atopic dermatitis, with Eric Simpson, MD walking through the readout for HCPLive. Full trial numbers remain pending publication.
Topic
Easi 75
Topic